Polsinelli, Angelina J.Wonderlin, Ryan J.Hammers, Dustin B.Pena Garcia, AlexEloyan, AniiTaurone, AlexanderThangarajah, MaryanneBeckett, LaurelGao, SujuanWang, SophiaKirby, KalaLogan, Paige E.Aisen, PaulDage, Jeffrey L.Foroud, TatianaGriffin, PercyIaccarino, LeonardoKramer, Joel H.Koeppe, RobertKukull, Walter A.La Joie, RenaudMundada, Nidhi S.Murray, Melissa E.Nudelman, KellySoleimani-Meigooni, David N.Rumbaugh, MaliaToga, Arthur W.Touroutoglou, AlexandraVemuri, PrashanthiAtri, AlirezaDay, Gregory S.Duara, RanjanGraff-Radford, Neill R.Honig, Lawrence S.Jones, David T.Masdeu, JosephMendez, Mario F.Womack, KyleMusiek, ErikOnyike, Chiadi U.Riddle, MeghanRogalski, EmilySalloway, StevenSha, Sharon J.Turner, Raymond S.Wingo, Thomas S.Wolk, David A.Carrillo, Maria C.Dickerson, Bradford C.Rabinovici, Gil D.Apostolova, Liana G.LEADS Consortium2023-09-202023-09-202023Polsinelli AJ, Wonderlin RJ, Hammers DB, et al. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort [published online ahead of print, 2023 Jun 9]. Alzheimers Dement. 2023;10.1002/alz.13344. doi:10.1002/alz.13344https://hdl.handle.net/1805/35671Introduction: We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Methods: Baseline NPS (Neuropsychiatric Inventory - Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups - amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70). Results: Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. Discussion: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD. Keywords: early-onset Alzheimer's disease; early-onset dementia; mild cognitive impairment; neuropharmacology; neuropsychiatric symptoms; psychotropic medications.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalEarly-onset Alzheimer’s diseaseEarly-onset dementiaMild cognitive impairmentNeuropharmacologyNeuropsychiatric symptomsPsychotropic medicationsArticle